Anti-inflammatory effect of high-dose insulin treatment after urgent coronary revascularization surgery

Acta Anaesthesiol Scand. 2006 Sep;50(8):962-9. doi: 10.1111/j.1399-6576.2006.01100.x.

Abstract

Background: The administration of insulin has been shown to exert cardioprotective and immunomodulatory properties. Ischemia and inflammation are typical features of acute coronary syndrome, thus it was hypothesized that high-dose glucose-insulin-potassium (GIK) treatment could suppress the systemic inflammatory reaction and attenuate myocardial ischemia-reperfusion injury in patients with unstable angina pectoris after urgent coronary artery bypass surgery.

Methods: Forty patients with unstable angina pectoris scheduled for urgent coronary artery bypass surgery and cardiopulmonary bypass were randomly assigned to receive either high-dose insulin treatment (short-acting insulin 1 IU/kg/h with 30% glucose 1.5 ml/kg/h administered separately) or control treatment (saline). Blood glucose levels were targeted to 6.0-8.0 mmol/l in both groups by adjusting the rate of glucose infusion in the GIK group and by additional insulin in the control group as needed.

Results: High-dose insulin treatment was associated with significantly lower average C-reactive protein (23.8 vs. 40.1 mg/l, P= 0.008) and free fatty acid levels (0.22 vs. 0.41 mmol/l, P= < 0.001) post-operatively. Average blood glucose levels were comparable during the intensive care unit (ICU) stay (7.1 vs. 6.9 mmol/l, P= 0.5) and 95% of the control patients received supplemental insulin. The pro-inflammatory cytokine response [interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-alpha)] did not differ between the groups and beneficial effects on myocardial injury were not detected.

Conclusions: High-dose insulin treatment has potential anti-inflammatory properties independent of its ability to lower blood glucose levels. Even profound suppression of free fatty acid levels, the attenuation of myocardial ischemia-reperfusion injury was not detected.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Angina, Unstable / surgery*
  • Biomarkers / metabolism
  • Blood Glucose / metabolism
  • C-Reactive Protein / drug effects
  • Cardioplegic Solutions / administration & dosage
  • Emergency Treatment
  • Fatty Acids, Nonesterified / metabolism
  • Female
  • Glucose / administration & dosage*
  • Humans
  • Inflammation / prevention & control*
  • Insulin / administration & dosage*
  • Interleukin-10 / metabolism
  • Interleukin-6 / metabolism
  • Male
  • Middle Aged
  • Myocardial Reperfusion Injury / prevention & control*
  • Myocardial Revascularization* / methods
  • Potassium / administration & dosage
  • Prospective Studies
  • Treatment Outcome

Substances

  • Biomarkers
  • Blood Glucose
  • Cardioplegic Solutions
  • Fatty Acids, Nonesterified
  • Insulin
  • Interleukin-6
  • glucose-insulin-potassium cardioplegic solution
  • Interleukin-10
  • C-Reactive Protein
  • Glucose
  • Potassium